Department of Vermont Health Access  
Pharmacy Benefits Management Program  
**DUR Board Meeting Agenda**  

June 3, 2014  6:00 – 8:15 p.m.  
*** Please note new times ***

1. **Executive Session**  
   6:00 - 6:15  
   ▪ Discussion on Medicaid OBRA’90/Supplemental Rebates and Agreements  
     (as provided by 33 VSA § 1998(f)(2))

2. **Introductions and Approval of DUR Board Minutes**  
   6:15 - 6:20  
   (Public Comment Prior to Board Action)

3. **DVHA Pharmacy Administration Updates**  
   6:20 - 6:30  
   ▪ Transition to new Pharmacy Benefit Manager (PBM) effective 1/1/2015  
   ▪ Updates

4. **Medical Director Update**  
   6:30 - 6:35  
   ▪ Clinical Programs Update  
   ▪ Prescriber Comments

5. **Follow-up Items from Previous Meetings**  
   6:35 – 6:50  
   ▪ Hepatitis C Medications – older agents (remove) and SVR4 with newer agents  
   ▪ Methadone – Letter to Prescribers

6. **RetroDUR/DUR**  
   6:50 – 7:00  
   ▪ Triptans for Migraine/Quantity Limits and Multiple Agents

7. **Clinical Update: Drug Reviews**  
   7:00 – 7:40  
   (Public comment prior to Board action)

   **Abbreviated New Drug Reviews**
   ▪ Aerospan® (flunisolide HFA) Inhalation Aerosol  
   ▪ Noxafil® (posaconazole) Oral Delayed-Release Tablet  
   ▪ Otrexup® (methotrexate) Subcutaneous Single-Dose Auto-Injector  
   ▪ Versacloz® (clozapine) Oral Suspension  
   ▪ Zorvolex® (diclofenac) Oral Capsule

   **Full New Drug Reviews**
   ▪ Fycompa® (perampanel) Film Coated Oral Tablets  
   ▪ Opsumit® (macitentan) Oral Tablet
8. Therapeutic Drug Classes – Periodic Review 7:40 – 7:55
   (Public comment prior to Board action)
   ▪ Fentanyl Immediate Release Products (includes review of Lazanda® (fentanyl nasal spray))
   ▪ Immunomodulators (new drug formulation – Actemra® (tocilizumab) Subcutaneous Prefilled Syringe)

   (Public comment prior to Board action)
   ▪ None

10. New Managed Therapeutic Drug Classes 7:55 – 7:55
    (Public comment prior to Board action)
    ▪ None

11. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products 7:55 – 8:05
    (Public comment prior to Board action)
    ▪ Analgesics: Long Acting Narcotics (new FDA language for indication)
    ▪ Alzheimer’s Agents: Namenda® XR – manufacturer to discontinue Namenda® IR

12. General Announcements 8:05– 8:15
    Selected FDA Safety Alerts
    ▪ Epidural Corticosteroid Injection: Drug Safety Communication - Risk of Rare But Serious Neurologic Problems
    ▪ Eszopiclone Containing Sleep Aids: Drug Safety Communication - Can Cause Next-Day Impairment – Recommend 1 mg Starting Dose
    ▪ FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin

13. Adjourn 8:15